A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).
Takayuki Yoshino
Consultant or Advisory Role - Takeda
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Takeda; Yakult
Research Funding - Bayer; Daiichi Sankyo; ImClone Systems; Taiho Pharmaceutical
Kentaro Yamazaki
No relevant relationships to disclose
Motoki Yoshida
No relevant relationships to disclose
Mark Daniel Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Naoto Yoshizuka
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Atsushi Ohtsu
Consultant or Advisory Role - Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical; Takeda
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Merck Serono; Pfizer; Taiho Pharmaceutical; Takeda; Yakult